Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC

Johanna C. Bendell, MD
Published: Thursday, Jan 04, 2018



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

For patients with MSI-H disease, they can still have the general standard chemotherapies that are still available to them, as well as targeted agents following progression on checkpoint inhibitor therapy, explains Bendell.

If a patient progresses on the checkpoint inhibitor, they could potentially go on to regorafenib (Stivarga), TAS-102 (Lonsurf), or a clinical trial. According to Bendell, there are many clinical trials that are looking at combinations for patients who have progressive disease following single-agent immunotherapies.
 


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

For patients with MSI-H disease, they can still have the general standard chemotherapies that are still available to them, as well as targeted agents following progression on checkpoint inhibitor therapy, explains Bendell.

If a patient progresses on the checkpoint inhibitor, they could potentially go on to regorafenib (Stivarga), TAS-102 (Lonsurf), or a clinical trial. According to Bendell, there are many clinical trials that are looking at combinations for patients who have progressive disease following single-agent immunotherapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x